Madeira Beach, FL – Andrew P. Mandell – Mr. Diabetes®, Executive Director of Defeat Diabetes Foundation and diabetes advocate announced today that he will be sitting on the ProtoKinetix (PKTX) Advisory Board. ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycoproteins (AAGP™) for medicine and the biotechnology and cosmetic industries.
“I’m really excited about their technology and it’s potential to offer the first truly viable long term treatment for diabetes,” said Mandell. “The Protokinetix’s research team has made remarkable progress in the harvesting and preservation of stem cells for islet transplantation for diabetes treatments,” he continued.
“In addition to the potential treatments for diabetes, AAGP™ also shows great promise in many other medical applications. I’m really looking forward to contributing where I can to support their work,” Mandell concluded.
About Defeat Diabetes Foundation
Defeat Diabetes Foundation is a 501(c)(3) nonprofit whose mission is the prevention, early identification and effective self management of diabetes.
DDF has awareness and interactive programs in all 50 states to provide critical information and education programs with a focus on diabetes, nutrition and physical fitness. Their public information programs include the KIDD™ Project which has provided millions of Free Defeat Diabetes® Screening Test brochures to schools in all 50 states, the DAN Project, a Public Service Announcements program and the Martial Arts Defeat Diabetes® Community Action Project (MADDCAP™) a historic health curriculum for martial arts schools and their students.
For information on diabetes, to take the free screening test or obtain additional information visit: http://www.defeatdiabetes.org/
For information on ProtoKinetix visit the website at: www.protokinetix.com
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.